Osteoarthritis and cartilage
-
Osteoarthr. Cartil. · Dec 2013
Multicenter StudyAnxiety and depressive symptoms before and after total hip and knee arthroplasty: a prospective multicentre study.
A subset of patients with total hip arthroplasty (THA) or total knee arthroplasty (TKA) has suboptimal postoperative results in terms of Patient Reported Outcomes (PROs), and psychological factors could contribute to these suboptimal results. ⋯ Preoperatively, the prevalence of anxiety and depressive symptoms was high. At 3 and 12 months postoperatively, the prevalence of anxiety and depressive symptoms was decreased in both hip and knee patients. However, patients with preoperative anxiety and depressive symptoms had worse PROs 3 and 12 months after THA and TKA and were less satisfied than patients without anxiety or depressive symptoms.
-
Osteoarthr. Cartil. · Dec 2013
Cross-cultural adaptation, reliability, internal consistency and validation of the Arabic version of the knee injury and osteoarthritis outcome score (KOOS) for Egyptian people with knee injuries.
The objective of this study was to cross-culturally adapt and validate the Arabic version of the Knee injury and Osteoarthritis Outcome Score (KOOS) among a sample from Egyptian populace. ⋯ The Arabic KOOS is a reliable and valid instrument that can be self-administered to Egyptian patients and provides a valuable basis for research and clinical projects focussing on patient-based assessments in anterior cruciate ligament (ACL), meniscus and combined injures of knee. Further studies to validate the Arabic version of the KOOS using females and elderly population with different knee problems and various educational levels in other Arabic counties are highly recommended.
-
Osteoarthr. Cartil. · Dec 2013
Exclusion of patients with sequential primary total joint arthroplasties from arthroplasty outcome studies biases outcome estimates: a retrospective cohort study.
Total joint arthroplasty (TJA) outcome studies have largely focused on recipients of a single primary TJA, which may bias outcome estimates. ⋯ One in five patients receiving their first elective primary hip or knee TJA received a second hip/knee TJA within 2 years. Our results indicate that exclusion of this large subsample of TJA recipients from TJA outcomes studies over-estimates surgical risks and may underestimate patient-reported benefits.
-
Osteoarthr. Cartil. · Dec 2013
Histone deacetylase inhibitors increase microRNA-146a expression and enhance negative regulation of interleukin-1β signaling in osteoarthritis fibroblast-like synoviocytes.
MiR-146a exerts negative control on inflammatory responses by suppressing cytokine-induced expression of interleukin-1 receptor-associated kinase-1 (IRAK1) and tumor necrosis factor receptor-associated factor 6 (TRAF6) by impairing NF-κB activity and inhibiting the expression of target genes. Recent study suggests that histone deacetylases (HDACs) are involved in the regulation of microRNA (miRNA) expression. Therefore, we determined whether HDAC inhibitors can increase miR-146a expression, thereby inhibiting interleukin-1β (IL-1β)-induced signaling in osteoarthritis fibroblast-like synoviocytes (OA-FLS). ⋯ Our study demonstrated that HDAC inhibitor treatment in OA-FLS significantly increased miR-146a expression and mediated markedly negative regulation to inhibit IL-1β-induced signaling and cytokine secretion. Our results indicate the potential rationale of anti-inflammatory effects for HDAC inhibitors.
-
Osteoarthr. Cartil. · Dec 2013
Intra-articular injection of the selective cyclooxygenase-2 inhibitor meloxicam (Mobic) reduces experimental osteoarthritis and nociception in rats.
To study the effect of intra-articular injection of meloxicam (Mobic) on the development of osteoarthritis (OA) in rats and examine concomitant changes in nociceptive behavior and the expression of mitogen-activated protein kinases (MAPKs) in articular cartilage chondrocytes. ⋯ Intra-articular injection of meloxicam (1) attenuates the development of OA, (2) concomitantly reduces nociception, and (3) modulates chondrocyte metabolism, possibly through inhibition of cellular p38 and JNK, but enhances ERK expression.